top of page

Aivia introduces machine learning and VR toolbox to accelerate brain research and drug development.

June 2017, (Bellevue WA, USA): Today DRVISION launched Aivia 5.1.

Aivia is revolutionizing academic and biomedical image analysis by democratizing powerful machine learning and virtual reality (VR) technologies. The tools now available in Aivia can accelerate research into treatments for Alzheimer’s, Parkinson’s, dementia, ALS and many other brain related conditions.

Machine learning classification algorithms have the potential to both minimize human biases and drastically increase the productivity both in a pharma/drug discovery setting and in academic research. First, Aivia captures the input provided by a domain expert while he reviews an image and shows it examples of each phenotype of interest. Second, the software autonomously extracts and categorizes numerous hidden features and in doing so, learns to identify the different phenotypes. Finally, the trained software can be used on other images resulting in the (automatic) detection of cell phenotypes of interest – a key procedure when learning about the healthy brain or when testing novel drugs.

Aivia is also pioneering the use of VR for the exploration of 3D/4D images. This visualization modality offers the most natural and insightful experience currently in existence. The user is immersed in the 3D/4D data set and has the freedom to walk around, look in any direction and intuitively interact with the shown objects (e.g. neurons and spines). This type of visualization often enables neuroscientists to see cellular relationships they had never seen before thus expanding our general understanding of neuronal structure and function.